The participating funds pursue the goal of concluding discount contracts for the active substance infliximab with all suitable pharmaceutical companies in accordance with Section 130a (8) SGB V. The contract is concluded as part of the open house biologics process of the participating funds:

Individual negotiations about the contents of the contract are not conducted, uniform conditions apply. The cash desks involved do not guarantee exclusivity to individual contractual partners. The contract period is a maximum of 12 months starting on April 1, 2022. The contract ends on 31.03.2023 at the latest, regardless of the date the contract was concluded. All further information can be found in the participation and contract documents.

It is possible to join this open house biological process at any time within the contract period.

A contract is concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration for approval and for the company) and confirm this with their signature.

This publication does not concern the award of a public contract within the meaning of the Procurement Law Directive (2014/24/EC) or antitrust procurement law. In the interest of informing interested pharmaceutical entrepreneurs as broadly as possible, this notice will be made in the supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text according to section IV.1.1) and the indication of award criteria in accordance with item II.2.5) are due to the specifications of the publication form and have no further meaning. This and the use of the medium “TED” does not involve any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.